You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1952 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Aug 2021
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Apr 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jan 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Jan 2024
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Soft Tissue, 
Uterine
Intent: Palliative, Adjuvant
Dec 2017
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2019
Statistical Reports

Pages